FDA isn't recommending label change for ADHD drugs

04/10/2011 | Reuters

The FDA is not requiring drugmakers to change usage and safety information for Shire's Adderall XR, Novartis' Ritalin and other stimulants for attention-deficit/hyperactivity disorder. The agency said it will provide an update after it finishes analyzing ADHD drugs' potential risk of cardiovascular events.

View Full Article in:

Reuters

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Site Quality Management
CareFusion
Minneapolis, MN
Clinical Project Manager
Abiomed, Inc.
Danvers, MA
Sr. Manager, Regulatory Affairs - International
Integra LifeSciences
Plainsboro, NJ
Associate - Food and Drug
Keller and Heckman LLP
Washington, DC
Market Access Manager Electrophysiology HEOR (AEP) - 15000003NZ
Abbott
Menlo Park, CA